Amplicon-based nanopore minion sequencing of patients with COVID-19 omicron variant from India

Introduction

Coronavirus Disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has been an unfolding saga as the most discussed disease in recent times (www.who.int last accessed December 23, 2021; Zheng et al. 2020; Kaur et al., 2021). As of December 23, 2021, there have been 277,575,992 confirmed cases of COVID-19, including 5,395,365 deaths, reported to WHO. Although over 8,158,815,265 vaccine doses have been administered, with the emergence of delta and recent omicron variants, there have been several deaths all over the world. As re-infections are on rise, the scientific community has focused its attention to understand and gain evidence in lieu of wading immunity (Kai and Gratchen et al, 2021). As on December 23, 2021, over 87 countries have reported omicron variants ever since the first case was reported on December 1, 2021 (Bai et al. 2021). India has also seen 213 omicron cases with 4,79,000 deaths and over 29.8 million recovered so far (as on December 23, 2021). Early signs from previous reports indicate that omicron causes mild symptoms and the incidental findings would allow us to discern the modality behind emerging variants from India. Understanding the omicron variants would also help facilitate better prophylaxis on comorbidities with clinical presentations thereby distinguishing patterns associated with infection.

Materials and Methods

Data pipeline and phylogenetic analysis

After the library preparation was done, careful execution of bar codes were supplied with the samples which were later run through MinKnow for approximately 3 hours so as to obtain fast5 files. The fast5 files were converted to fastq and a final annotation report was obtained through a series of steps. Commander was used to streamline the report as the workflow ensured all barcodes were run through quality check, amplicon coverage, genome coverage, variant calling and VCF file generation (https://genotypic.co.in/Commander; last accessed December 23, 2021). A 20x mean coverage of ca. 96.28% raw reads were mapped to SARS-CoV-2 reference genomes (accessions MN908947.3/NC_0145512), and a few sequences indicative of variable coverage (‘N’ or ‘X’). Using the initial set of these sequences, we have taken ‘‘good-sequence’’ alignment of all 13 omicron cases from India aligned to Wuhan reference, and a neighborhood joining tree was constructed using clustal omega with the sequences sorted vertically, thereby drawing a circular and unrooted tree (Sievers et al. 2011; Figure 1c/d). The tree was later visualized using interactive tree of life (iTOL; etunic and Bork et al. 2021). Finally, the GIASIA’s audacity instance was used to identify the mutations in spike glycoprotein and calculate the neighbor distance between related sequences, and datawrapper (datawrapper.de last accessed December 23, 2021) was used to plot the sequence data. All the 13 sequences were uploaded to the Global Initiative for Sharing All Influenza Data (GISAID) (Elbe and Buckland-Merrett, 2017) submission making data available for free access.

• Download figure
• Open in new tab

Figure 1:

(a) Samples attributing to 20X coverage; (b) Neighborhood distance with quality check of closely related sequences (c)Circular phylogenetic tree of all 13 samples from India claded with Wuhan reference genome. (d) Unrooted tree showing a clear dissection of Wuhan from other lineages

Results and Discussion

The ONT minion yielded a total read length attributing to 25 million reads on an average from all 13 samples, and the genomic GC content varied from ca. 40 to 43% covering 96.28% of the SARS-CoV-2 genome (20x) (Table 1; Figure 1a). To check the transmissibility associated with the number of mutations in the spike glycoprotein associated with receptor-binding domain (RBD), we compared the 44 common mutations from our samples with the recently emerging mutations of omicron (Figure 2). Our preliminary analysis indicate that the omicron variant subcladed with the dominant Delta variant and might have evolved rapidly from the multiple mutations in spike proteins further interacting with the angiotensin converting enzyme 2 (ACE2) receptor or Ab/IFN-gamma (Supplementary Tables 1-4; Figure 2).

• Download figure
• Open in new tab

Figure 2:

The spike mutations (#35) seen in Indian sub-population with the nearest residue if in loop/termini region (A67V, V70I(69), T95I, G142V, Y145H(143), N211I, L212I, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H T547K, D614G, H655Y, N679K(674), P681H(674), A701V, N764K, D796Y, N856K, Q954H, N969K, L981F). (a) spike glycoprotein (PDB: 6acc, EM 3.6 Angstrom) with RBD in down conformation. (b) (b) Multivenn diagram of three samples LNHD1, LNHD8 and LNHD9 showing exclusively unique mutations in those samples and those common to all the LNHD series; (c) spike glycoprotein (PDB: 6acj, EM 4.2 Angstrom) in complex with host cell receptor ACE2 (green ribbon). See supplementary Table 1 for details

From the phylogenetic analysis, we observed that the Indian omicron variants were clustered together with a root emerging from OL815455, the variant that was first detected from Botswana. The iTOL containing the 13 sequenced samples and Wuhan reference yielded distinct clades both in unrooted and rooted circular tree, and the four samples that were claded separately perhaps indicate that they were among the first suspects of omicron in India (https://cov-lineages.org/lineages). With over 56 published omicron variants inGisaid.org from India (as on December 23, 2021), sequence comparison with Illumina short reads would allow us to understand the efficacy of third wave and inclination for possible herd immunity.

The neighborhood distance of closely related sequences from our LNHD series when compared to that of the entire GISAID EpiCoV database revealed that LNHD9 (with D155Y mutation) has a distinct clade with GBRC3290, a sample from Gujarat that was submitted recently. Both the samples with GR clade carry a combination of nucleocapsid, spike and NS3 mutations in addition to spike D614G (Sengupta et al. 2021). Taken together, we sought to ask whether or not any samples from our cohort have common and exclusively unique mutations. We obtained p.Thr614Ile, p.Thr1822Ile, p.Thr6098Ile, p.Asp155Tyr from LNHD9, p.Ala701Val and p.Val1887Ile from LNHD8 and p.Gly667Ser from LNHD1 (Figure 2c) with other samples having all common mutations reported (Supplementary Table 3). However, our preliminary observations indicate that none of these are known to be detrimental to the spike (Pires et al. 2014; data not shown). Mutations in the spike proteins of SARS-CoV-2 variants of concern (VoC) have also been compared to the parental SARS-CoV-2 isolate B.1 suggesting that the amino acid substitutions are already found in altered positions but with distinct substitutions. Finally, a large number of samples matching up to the sequence with neighbor distance of 0 and 2 (and a few with neighbor distance 4) showed that the mutational load or overburden could be attributed from delta or previous lineages (BA. 1; Supplementary Table 5)

The outbreak of COVID-19 caused by SARS-CoV-2 has swiftly spread worldwide with the probable origin of omicron still unclear. Interestingly, all the emerging case reports with no or mild upper respiratory tract symptoms are either with asymptomatic or oligosymptomatic transmission (Kupferschmidt K and Vogel G, 2021). The limitation of our study is that although the adopted ARCTIC protocol allowed the confirmation of SARS-CoV-2 infections, given the urgent need for rapid identification and traceability of omicron variants, an indefatigable checking the antibody titer against deleterious mutations and subsequent single cell genomic assay would have been a better proposition (Kannan et al. 2022). Furthermore, the difference in viral loads among samples will possibly affect the stability of average depth and genome-wide coverage with increase in whole-genome mapping. In summary, our study has demonstrated the utility of nanopore sequencing for SARS-CoV-2 genomes from clinical specimens. We firmly hope that prompt diagnosis and rapid whole-genome analysis would allow a decisive response to the SARS-CoV-2 outbreak that will bring disease control and prevention efforts.

Competing interests

None

Authors’ contributions

SK, AL, SKP, SCOG members performed library preparation and ran the ONT Minion., PS, SK, SKP and MF performed bioinformatics and genomic analysis., OS crosschecked the clinical spectrum of samples., SKu and SKa co-led the investigation and surveillance of the project., SK, SKP and PS wrote the draft and proofread the manuscript before all authors agreeing to the final version.

Data availability

All omicron variant samples have been uploaded to GISAID.org with hCoV-19/India/un-LNHDXX/2021 series

SARS COV2 CONSORTIUM: Maulana Azad Medical College & Associated Lok Nayak Hospital (SCOG_MAMC_LNH)*

1. Dr Suresh Kumar, Medical Director, LNH and Head of Department of Medicine, Maulana Azad Medical College, New Delhi

2. Dr. Anurag Aggarwal, Director, CSIR, IGIB, New Delhi-

3. Dr. Sujeet Singh, Director, NCDC, New Delhi

4. Dr. Seema Kapoor, Director Professor, Department of Pediatrics, Maulana Azad Medical College, New Delhi.

5. Dr Sonal Saxena, Director Professor & Head of Department, Department of Microbiology, Maulana Azad Medical College, New Delhi.

6. Dr B.C.Koner, Director Professor and Head, Department of Biochemistry and Chairman, Medical research Unit Maulana Azad Medical College, New Delhi

7. Dr M.M. Singh, Director Professor, Dept of Community Medicine, Maulana Azad Medical College, New Delhi

8. Dr Vikas Manchanda, Professor, Department of Microbiology, Maulana Azad Medical College, New Delhi.

9. Dr Sandeep Garg, Professor, Department of Medicine, Maulana Azad Medical College, New Delhi

10. Dr Pragya Sharma, Professor, Dept of Community Medicine, Maulana Azad Medical College, New Delhi

11. Dr. Rajesh Pandey, Senior Scientist, CSIR IGIB, New Delhi

12. Dr. Mohamed Faruq, Principal Scientist, CSIR IGIB

13. Dr Sunil K Polipalli, Cytogeneticist, Genetic Lab, Department of Pediatrics, Lok Nayak Hospital, New Delhi.

14. Dr Oves Siddiqui, Associate Professor, Department of Microbiology, Maulana Azad Medical College, New Delhi.

15. Dr. Himanshu Chauhan, Additional Director, NCDC, New Delhi

16. Dr. Arvind Mohan, Medical Officer, Department of Medicine, Maulana Azad Medical College, New Delhi

17. Dr. Meenakshi Bothra, Assistant Professor, Department of Pediatrics, Maulana Azad Medical College, New Delhi.

18. Dr. Ranjana Mishra, Medical Officer, Thalassemia Screening programme, Lok Nayak Hospital. New Delhi.